β-Boswellic acid

Pharmacology & Research

β-Boswellic acid (BBA) is a pentacyclic triterpene acid and one of the most abundant boswellic acids in frankincense (Boswellia serrata) resin ^{9Reference 9Mannino G et al. · 2016Quantitative determination of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and other boswellic acids in Boswellia sacra Flueck and Boswellia serrata RoxbView study →}. The single most important framing point is a family distinction: frankincense’s anti-inflammatory reputation rests on the 11-keto boswellic acids — AKBA and KBA — which are the potent 5-lipoxygenase inhibitors and the standardisation markers of Boswellia extracts. BBA lacks the C-11 keto group, so it is a weak and different actor on 5-LOX ^{1Reference 1Sailer ER et al. · 1996Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activityView study →}; its own preclinical mechanisms run through cathepsin G, topoisomerase and NF-κB instead ^{2,3,4Reference 2Tausch L et al. · 2009Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincenseView study →Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →Reference 4Syrovets T et al. · 2005Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinasesView study →}. Two further facts shape the page: all human “Boswellia” efficacy is for the whole extract standardised to boswellic acids, not isolated BBA ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →}, and boswellic acids have poor oral bioavailability that improves substantially with a fatty meal ^{6,7Reference 6Sterk V et al. · 2004Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteersView study →Reference 7Skarke C et al. · 2012Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteersView study →}.

1. Anti-inflammatory (OA, IBD)

The application with human data — but the human data are the extract. Standardised B. serrata extract improved knee-osteoarthritis pain and function with reduced hs-CRP and MMP-3 in a placebo-controlled trial ^{11Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →}, and a boswellic-acid extract reduced radiotherapy-associated cerebral edema in a controlled trial ^{12Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →}. BBA is an abundant pair-member of those extracts and contributes anti-inflammatory signalling via cathepsin G and IKK/NF-κB ^{2,4Reference 2Tausch L et al. · 2009Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincenseView study →Reference 4Syrovets T et al. · 2005Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinasesView study →}.

Gap: every human result is the multi-component extract whose leukotriene-pathway potency is carried by AKBA/KBA, not BBA (which lacks the 11-keto needed for strong 5-LOX inhibition ^{1Reference 1Sailer ER et al. · 1996Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activityView study →}); no isolated-BBA human trial exists ^{11Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →}.

2. Anticancer

Boswellic acids trigger caspase-8-dependent apoptosis in HT-29 colon cancer cells, independent of Fas/FasL ^{5Reference 5Liu JJ et al. · 2002Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent of Fas/Fas-ligand interaction in colon cancer HT-29 cellsView study →}, and acetyl-boswellic acids act as catalytic inhibitors of human topoisomerase I and IIα ^{3Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →}, as reviewed ^{10Reference 10Efferth T · 2022Anti-inflammatory and anti-cancer activities of frankincense: targets, treatments and toxicitiesView study →}.

Gap: in-vitro and rodent, and the strongest apoptosis/topoisomerase data attach to the acetylated and keto congeners, not consistently to free BBA — with no BBA-isolate in-vivo tumour study and no human oncology data ^{3,5Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →Reference 5Liu JJ et al. · 2002Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent of Fas/Fas-ligand interaction in colon cancer HT-29 cellsView study →}.

3. Cathepsin-G inhibition

Human cathepsin G was identified as a functional target of boswellic acids from frankincense; inhibiting this serine protease reduces chemotaxis and inflammatory signalling — a BBA-plausible, keto-independent mechanism distinct from the AKBA 5-LOX story ^{2Reference 2Tausch L et al. · 2009Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincenseView study →}.

Gap: mechanistic (isolated enzyme and cell assays), with no whole-animal or human efficacy endpoint tied to the target ^{2Reference 2Tausch L et al. · 2009Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincenseView study →}.

4. Topoisomerase / NF-kB

Acetyl-boswellic acids inhibit topoisomerase I/IIα ^{3Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →} and block LPS-induced TNF-α by directly interacting with the IκB kinases, i.e. upstream NF-κB suppression ^{4Reference 4Syrovets T et al. · 2005Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinasesView study →}.

Gap: demonstrated for the acetylated boswellic acids — free BBA’s potency at these targets is weaker and less characterised, so attribute cautiously ^{3,4Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →Reference 4Syrovets T et al. · 2005Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinasesView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
5-Lipoxygenase	↓ leukotriene synthesis — weak for BBA (no C-11 keto)	anti-inflammatory — the potent actor is AKBA/KBA
Cathepsin G (serine protease)	direct inhibition → ↓ chemotaxis/inflammation	BBA-plausible, keto-independent route
Topoisomerase I & IIα	catalytic inhibition	anticancer (acetyl-boswellic acids)
IKK → NF-κB → TNF-α	↓ IKK → ↓ NF-κB → ↓ TNF-α	anti-inflammatory (acetyl-boswellic acids)
Caspase-8 / apoptosis	apoptosis independent of Fas/FasL	anticancer (colon cell lines)

Pharmacokinetics

Load-bearing and the honest limiter. Boswellic acids have poor oral bioavailability — high lipophilicity, low aqueous solubility, and extensive first-pass handling and efflux limit systemic and CNS exposure, and an in-vitro panel of the six major boswellic acids found sharply differing permeability and metabolic stability with limited predicted brain availability ^{8Reference 8Gerbeth K et al. · 2013In-vitro metabolism, permeation and brain availability of six major boswellic acids from Boswellia serrata gum resinsView study →}. Crucially, a high-fat meal markedly increases absorption: a standardised fatty meal raised plasma boswellic-acid levels in healthy volunteers ^{6Reference 6Sterk V et al. · 2004Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteersView study →}, and specifically increased 11-keto-β-boswellic acid exposure several-fold after a single frankincense-extract dose ^{7Reference 7Skarke C et al. · 2012Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteersView study →}. KBA and AKBA are the routinely measured plasma markers; BBA, though abundant in the resin, is used less often as the quantitative marker. The practical implication: dose with a fatty meal, because unfed absorption is poor.

Clinical trials

There is no human trial of isolated β-boswellic acid. The human evidence base is the whole B. serrata extract standardised to boswellic acids — a knee-osteoarthritis RCT ^{11Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →} and a cerebral-edema RCT ^{12Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →} — in which BBA is present as an abundant constituent but is not the standardisation target and cannot be credited as the isolated active.

Last checked: July 2026.

Toxicity & Safety

Boswellia serrata extract is generally well tolerated in trials, with the most-reported effects being mild gastrointestinal upset (nausea, reflux, diarrhoea) ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →}; there is no isolated-BBA human safety data. Boswellic acids modulate cytochrome-P450 activity in vitro, a plausible but unproven basis for interactions with CYP-metabolised drugs, and additive caution with anti-inflammatory or anticoagulant regimens is prudent given the fraction’s leukotriene/NF-κB activity. One family caveat: the potency and safety signals differ across the boswellic acids — a developmental/cardiotoxicity signal reported in zebrafish applies to AKBA, not BBA, and should not be transferred here, though it is a reminder the family is not uniformly benign.

Pregnancy & lactation

Avoid. Boswellia/frankincense carries a traditional emmenagogue/uterine-stimulant reputation, and there are no reproductive-safety data for isolated BBA or the extract — avoid in pregnancy, and with insufficient lactation data, avoid there too.

Dosage

There is no validated human dose for isolated β-boswellic acid, and nothing here is a recommendation. Human data use standardised B. serrata extract — commonly ~100–250 mg/day of a high-AKBA extract, or ~300–400 mg two to three times daily of a ~30–65% boswellic-acid extract in older osteoarthritis trials ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →} — and absorption improves substantially when taken with a fatty meal ^{6,7Reference 6Sterk V et al. · 2004Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteersView study →Reference 7Skarke C et al. · 2012Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteersView study →}. Those figures describe the extract in which BBA occurs, not the isolated molecule.

References